Interlaw’s partner firm in Denmark, Mazanti-Andersen has advised shareholders of Nordic Bioscience in leading global investment firm, KKR’s acquisition of a minority equity stake in the business.

Mazanti-Anderson advised the existing shareholders throughout the process with a team led by partners Henrik B. Sanders, Jakob Mosegaard Larsen and Thomas Weisbjerg. This marks the firm’s fourth transaction within the life sciences and pharma sector in 2021, underlining its strong position and expertise in executing successful transactions across the field.   

Nordic Bioscience is a world leader in biomarker development, specializing in precision medicine using unique biomarker technologies. The Danish-based company has established a position as the world’s most experienced company in the extracellular matrix (ECM) through more than 25 years of dedicated research and development. The ECM is the non-cellular component of all tissues and organs and can be analyzed to identify new drug candidates in more than 50 disease areas, diagnose patients and evaluate the effect of existing drugs and drug candidates. The company owns more than 150 patents and has entered into partnerships with the world’s largest pharma companies to develop new drugs in four major disease areas (fibrosis, oncology, diabetes and cardiovascular).   

KKR has invested approximately $14 billion in equity capital across the health care sector since 2004 and the investment in and partnership with Nordic Bioscience will support the company in building on its strategy of bringing innovative novel diagnostic biomarkers and drug candidates to the market for the benefit of patients.